



ASX / MEDIA RELEASE

2nd March 2017

Share Buyback – Update

Sydney, Australia: 2nd March 2017 – Sirtex Medical Limited (ASX:SRX) announced today that, following a threatened injunction from the Applicant in the representative proceeding to stop the Company's proposed on-market share buyback, on the basis he alleges that the implementation of the share buyback will materially prejudice Sirtex's ability to satisfy any liability arising in respect of the claims made in the representative proceeding under s257A(a) of the Corporations Act. The Board has agreed to delay the commencement date for the buyback from 9th March 2017 to 27th March 2017, while the Company addresses the Applicant's allegation.

About Sirtex Medical

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer. Over 73,000 doses have been supplied to treat patients with liver cancer at 1,060 medical centres in over 40 countries. For more information please visit www.sirtex.com.

For further information, please contact:

Investor Enquiries:

Mr Darren Smith
CFO & Company Secretary
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy
Global Investor Relations Manager
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

Head Office

Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas

300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa

Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific

50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406

Appendix 3D

Changes relating to buy-back (except minimum holding buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/9/99. Origin: Appendix 7B. Amended 13/3/2000, 30/9/2001, 11/01/10

Name of entity	ABN/ARSN
SIRTEX MEDICAL LIMITED	35 078 166 122

We (the entity) give ASX the following information.

1	Date that an Appendix 3C or the last Appendix 3D was given to ASX	22 February 2017
---	---	------------------

Information about the change

Complete each item for which there has been a change and items 9 and 10.

	Column 1 (Details announced to market in Appendix 3C or last Appendix 3D)	Column 2 (Details of change to buy-back proposals)
On-market buy-back		
2	Name of broker who will act on the company's behalf	
3	Deleted 30/9/2001.	
4	If the company/trust intends to buy back a maximum number of shares/units – that number Note: This requires a figure to be included, not a percentage. The reference to a maximum number is to the total number including shares/units already bought back and shares/units remaining to be bought back. If the total has not changed, the item does not need to be completed.	
	Column 1 (Details announced to market in Appendix 3C or last Appendix 3D)	Column 2 (Details of change to buy-back proposals)

⁺ See chapter 19 for defined terms.

Appendix 3D

Changes relating to buy-back

5	If the company/trust intends to buy back a maximum number of shares/units – the number remaining to be bought back		
6	If the company/trust intends to buy-back shares/units within a period of time – that period of time; if the company/trust intends that the buy-back be of unlimited duration - that intention	<p>The Company intends to buy-back shares in the period 9 March 2017 to 8 September 2017 (inclusive) or earlier if the maximum number of shares in item 11 above is bought back prior to that date.</p> <p>The Company reserves the right to suspend or terminate the buy-back at any time.</p>	<p>The Company intends to buy-back shares in the period 27 March 2017 to 8 September 2017 (inclusive) or earlier if the maximum number of shares in item 11 above is bought back prior to that date.</p> <p>The Company reserves the right to suspend or terminate the buy-back at any time.</p>
7	If the company/trust intends to buy back shares/units if conditions are met – those conditions		

All buy-backs

8	Any other change		
---	------------------	--	--

⁺ See chapter 19 for defined terms.

9 Reason for change

To allow sufficient time to respond to a threatened injunction as more fully detailed in the accompanying ASX release.

10 Any other information material to a shareholder's/unitholder's decision whether to accept the offer (*eg, details of any proposed takeover bid*)


Compliance statement

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.

or, for trusts only:

1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:


.....
(Director/Company secretary)

Date: 2 March 2017

Print name:

Darren Smith

== == == == ==

⁺ See chapter 19 for defined terms.